Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

  • STATUS
    Recruiting
  • End date
    May 4, 2023
  • participants needed
    5000
  • sponsor
    National Cancer Institute (NCI)
Updated on 23 October 2022
ct scan
cancer
lymphoma
multiple myeloma
tumor markers
metastasis
cancer diagnosis
primary cancer
solid tumor
metastatic solid tumor
immunostimulants
cytology specimen collection procedure

Summary

This research trial collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.

Description

PRIMARY OBJECTIVE:

I. To procure biologic tissues and materials to generate preclinical models of cancer.

OUTLINE

Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.

Details
Condition Lymphoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Plasma Cell Myeloma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma
Treatment cytology specimen collection procedure
Clinical Study IdentifierNCT02474160
SponsorNational Cancer Institute (NCI)
Last Modified on23 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients 18 year of age or older who are being evaluated, treated or enrolled in a clinical trial for cancer at participating sites
Patients with a histologically or cytologically confirmed diagnosis of cancer
Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician
Radiographic imaging (computed tomography [CT], magnetic resonance imaging [MRI], etc.)
Elevated tumor markers
Clinical symptoms
Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
If the patient will be undergoing surgical resection at a later time and will be
Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final redacted pathology confirmation must be provided to the coordinating site detailing the confirmed cancer diagnosis for patients enrolled based on the above criteria
accessible to approach for study participation at that time, resected material
Patients with a solid tumor, lymphoma or multiple myeloma malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by
following cancer diagnosis confirmation is preferred
Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR
Documentation by the treating physician of clinical disease progression
Patients with a newly diagnosed primary and/or metastatic solid tumor, lymphoma or
multiple myeloma malignancy for which they have not yet received treatment
Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)
Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)
Specimens should not be collected from patients between doses within a single treatment cycle
Patients with ongoing partial response (PR) or stable disease (SD) are eligible
Confirmation of viable malignancy and/or < 90% tumor necrosis must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology report
Confirmation of viable malignancy and/or < 90% tumor necrosis must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology report
Ability to understand and willingness to sign a written informed consent document
indicating their willingness to have their tissue or biologic fluid specimens
used for research as outlined in this protocol

Exclusion Criteria

Patients with invasive fungal infections
Patients with active and/or uncontrolled infections or who are still recovering from an infection
Actively febrile patients with uncertain etiology of febrile episode
All antibiotics should be completed at least 1 week (7 days) prior to collection
No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion
Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity
Patients that are anti-HAV IgG reactive only are eligible
Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e
quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or
positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus
[HCV]-ribonucleic acid [RNA]) or known history of HCV, HBV, or HIV; testing
for HBV, HCV, HIV or other infections for eligibility will be performed only
if clinically indicated
Specimen collections from patients with benign tumors including but not limited to
desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease
response (CR) based on imaging
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note